Iovance Biotherapeutics, Inc. (LON:0JDK)

Market Cap	653.88M
Revenue (ttm)	186.30M
Net Income (ttm)	-295.82M
Shares Out	n/a
EPS (ttm)	-0.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	191,509
Average Volume	109,345
Open	2.250
Previous Close	2.281
Day's Range	2.178 - 2.270
52-Week Range	1.570 - 8.560
Beta	0.83
RSI	48.88
Earnings Date	Mar 2, 2026

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2007
• Employees: 838
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JDK

Financial Performance

In 2024, Iovance Biotherapeutics's revenue was $164.07 million, an increase of 13698.99% compared to the previous year's $1.19 million. Losses were -$372.18 million, -16.18% less than in 2023.

Financial numbers in USD